KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash from Investing Activities (2017 - 2025)

Guardant Health's Cash from Investing Activities history spans 9 years, with the latest figure at -$905.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 8695.13% year-over-year to -$905.1 million; the TTM value through Dec 2025 reached -$627.2 million, down 140.02%, while the annual FY2025 figure was -$627.2 million, 140.02% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$905.1 million at Guardant Health, down from -$14.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $663.5 million in Q4 2023 and bottomed at -$905.1 million in Q4 2025.
  • The 5-year median for Cash from Investing Activities is $19.3 million (2024), against an average of $1.9 million.
  • The largest YoY upside for Cash from Investing Activities was 979.11% in 2025 against a maximum downside of 8695.13% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$266.7 million in 2021, then surged by 126.48% to $70.6 million in 2022, then skyrocketed by 839.38% to $663.5 million in 2023, then crashed by 98.41% to $10.5 million in 2024, then tumbled by 8695.13% to -$905.1 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Cash from Investing Activities are -$905.1 million (Q4 2025), -$14.4 million (Q3 2025), and -$10.6 million (Q2 2025).